Clinical Trial

Evaluation of PreveCol's Efficiency As a Second Line Method for the Early Colorectal Cancer Detection

Study acronym: MS-Prevecol
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 27, 2025 (before its estimated November 2025 completion). Its status may not reflect the trial's current state.
Summary
The objective of this low-risk interventional study is to evaluate whether the PreveCol® test has sufficient efficiency to be considered as a second-line method for the detection of both colorectal cancer and advanced adenomas when used prospectively in the screening population with a previous positive FOBT result, which could include any of the following: both sexes, age 50-69 years, asympthomatic volunteers. The main aims to be answered are: * Values of efficacy, efficiency, impact and safety of PreveCol. * Values of preferences of participants for screening methods. * Values of PREMs into screening programme. Participants will provide a blood sample prior to a screening colonoscopy, and complete two questionnaires. They will give their sample, information and clinical data to the investigator or health care personnel.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-11-21.
Status change: Not Yet Recruiting → Recruiting 2025-02-25
Trial Details
NCT Number NCT06703632
Lead Sponsor ADVANCED MARKER DISCOVERY S.L.
Collaborators: Hospital Universitario Ramon y Cajal, Hospital de Santa Maria, Lisbon
Conditions Screening for Colon Cancer, Blood Samples, Survey and Questionnaire, Colorectal Carcinoma, Colon Adenocarcinoma, Precancerous Lesion of Colon
Enrollment 4,538 participants
Start Date 2025-01-14
Primary Completion 2025-11 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-02-27